Oral peanut immunotherapy How much is too much? How much is enough?
to current knowledge challenging the feasibility of conventional approaches of OIT in clinical routine but also provides information that may support other than high-dose OIT approaches.
Patients with very low reaction thresholds and severe reactions
are perceived as those who would profit most from successful and safe OIT by raising the reaction threshold or even inducing complete tolerance development.
The authors discuss that they enrolled such a group of severely allergic patients compared to other studies. Although the majority of OIT trials included patients with a history of anaphylaxis and/or asthma, there are some aspects that make this cohort special. The authors applied a protocol for OFCs that required the presence of "at least two moderate objective symptoms in one or more organ systems according to PRACTALL consensus report." 3 Thus, all children had an anaphylaxis during OFC who might not have had an anaphylaxis during OFC if conventional stopping rules for OFCs were applied. Authors also argue that predominantly patients with a low threshold were enrolled and illustrate that in such a severely affected population, 75% of these patients can reach a maintenance dose that protects from accidental reactions due to cross contaminations but also highlights the low success rate in this group to reach a maintenance dose equivalent to a full serving (21%).
When discussing OIT to food, two parameters are key: the dose and the time. Data from high-dose immunotherapy using 3-10 g, lowdose OIT of <300 mg, 4 sublingual Immunotherapy with a very low dose of 1-5 mg of peanut protein, 5 and epicutaneous immunotherapy of (<1 mg) 6 have been summarized. 7 There seems to be a correlation between the number and severity of adverse reactions, dropout rates, and the amount of peanut protein applied (Figure 1 Currently, the dogma exists that higher doses are linked to a higher probability of developing sustained unresponsiveness or tolerance. But data are not consistent, and additional studies that directly compare different doses are needed. Since the primary aim of the still ongoing TAKE-AWAY trial is analysis of the induction of sustained unresponsiveness, results will help to further delineate this hypothesis. It may well be that the length of application is by far more important for tolerance development and low doses with less side effects are the future of oral immunotherapy.
The most significant factor responsible for the reduced quality of life in food allergic patients is the constant fear of having an accidental exposure. OIT-related gain of control and protection often outweighs the increased chance of an allergic reaction due to treatment. For some however, avoidance may be the better choice. 8 It is up to us as allergists to identify those patients who will profit from a treatment and define the aims accordingly. For the very severe cases, aiming for an increase in threshold may be more important than going for the loss of the allergy and risking a treatment failure due to side effects that cannot be tolerated.
New approaches to overcome the limitations of high-dose OIT and allow uncomplicated multi food OIT are demanded. Therefore, co-application of biologicals such as omalizumab allows a better safety profile 9 and possibly a significantly lower rate of treatment failures.
Moreover, novel treatment options such as hypoallergenic variants of allergens, allergen preparations that include potential pro-tolerogenic adjuvants, or peptide immunotherapy may improve the safety and efficacy profile of OIT.
In conclusions, the manuscript of Reier-Nilsen elegantly shows the efficacy of OIT with regard to desensitization, but more importantly raises concerns whether high-dose OIT has the potential, in its current version, to be applied as a standard treatment for food allergy. This applies in particular for patients who are highly sensitized, with a low threshold and a history of anaphylaxis. 
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